Company Announcement no. 23/2007
To: OMX Nordic Exchange Hørsholm, Denmark, September 10, 2007
LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act,
Section 28(a)
Summary: Report of transactions in LifeCycle Pharma shares and related
securities by persons discharging managerial responsibilities and
persons/companies closely associated with these.
Hørsholm, Denmark, September 10, 2007; Pursuant to the Danish Securities Trading
Act, Section 28(a), LifeCycle Pharma A/S (OMX:LCP) is required, on a daily
basis, to make public transactions in LifeCycle Pharma shares and related
securities by persons discharging managerial responsibilities and
persons/companies closely associated with these.
--------------------------------------------------------------------------------
| Name | Michael Wolff Jensen |
--------------------------------------------------------------------------------
| Reason for reporting | Chief Financial Officer |
--------------------------------------------------------------------------------
| Issuer and ID code/ISIN | LifeCycle Pharma A/S / DK0060048148 |
--------------------------------------------------------------------------------
| Type of transaction | Subscription of shares through |
| | exercise of warrants |
--------------------------------------------------------------------------------
| Date of transaction | September 10, 2007 |
--------------------------------------------------------------------------------
| Relevant market | OMX, Nordic Exchange |
--------------------------------------------------------------------------------
| Number of traded securities | 100,000 |
--------------------------------------------------------------------------------
| Market value (subscription price) | DKK 738,250 |
--------------------------------------------------------------------------------
About LifeCycle Pharma A/S ("LCP A/S"):
LCP A/S, headquartered in Hørsholm, Denmark, is an emerging specialty
pharmaceutical company focused on developing and commercializing a portfolio of
innovative products in therapeutic areas such as cholesterol management,
hypertension, organ transplantation and autoimmune diseases. LCP's proprietary
MeltDose® technology, offers lower dosing, reduced side effects, improved safety
and patient compliance, and reduced product development costs and times.
LCP-FenoChol, a fenofibrate for the treatment of hyperlipidemia and
hypertriglyceridemia, is LCP's first FDA approved product (approved in August
2007). LCP is listed on the OMX Nordic Exchange under the trading symbol
(OMX:LCP). For further information, please visit www.lcpharma.com.
Contact:
Michael Wolff Jensen
Executive Vice President and CFO
Tel. +45 70 33 33 00
Mob. +45 40 74 62 44
Email. mwj@lcpharma.com
---oo0oo---
LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a)
| Source: Veloxis Pharmaceuticals A/S
Attachments
